Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMP-001
- Development stage
- Unknown
- Lead developer
- IntegoGen
- Administration
- Intralesional
01
Overview
AMP-001 (also known as IGN-AMP001) is an allogeneic micronized amniotic membrane product developed by IntegoGen. It is designed as an injectable regenerative therapy for the treatment of chronic inflammatory skin conditions, specifically hidradenitis suppurativa. The product consists of processed human amniotic membrane, which is rich in growth factors, cytokines, and extracellular matrix proteins that promote tissue repair and modulate inflammation. In clinical studies, it is administered via intralesional injection to target the underlying pathology of skin lesions by providing a biological scaffold and a reservoir of bioactive molecules to facilitate healing.
- Other names
- Allogeneic Micronized Amniotic Membrane Product
Beyond the preview
Go deeper on AMP-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMP-001.